15 Leukemia Clinical Trials in Iowa City, IA (2026)

Q: How do I join a clinical trial in Iowa City?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Iowa City research site will contact you.

Recruiting Leukemia Studies in Iowa City

NCT05208762Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect i...

Iowa City, IAPHASE1714 participantsSeagen, a wholly owned subsidiary of Pfizer

View Study Details

NCT04065399Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled...

Iowa City, IAPHASE1447 participantsSyndax Pharmaceuticals

View Study Details

NCT05429632Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial....

Iowa City, IAPHASE3366 participantsPriothera SAS

View Study Details

NCT04317534Recruiting

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumor...

Iowa City, IAPHASE2244 participantsGreg Durm, MD

View Study Details

NCT07006727Recruiting

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged...

Iowa City, IAPHASE1116 participantsNovartis Pharmaceuticals

View Study Details

NCT07221500Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent...

Iowa City, IAPHASE2100 participantsNurix Therapeutics, Inc.

View Study Details

NCT06406777Recruiting

Chronic Lung Allograft Dysfunction MRI Study

This studies purpose is to confirm the efficacy and efficiency of using OE-MRI and MRI with hyperpolarized gas techniques and Iodinated contrast CT scan, this will enhance understanding of CLAD pathop...

Iowa City, IAPHASE1100 participantsSean Fain

View Study Details

NCT05903092Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer

The study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, sub...

Iowa City, IAPHASE284 participantsHirva Mamdani

View Study Details

NCT07109219Recruiting

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-AL...

Iowa City, IAPHASE183 participantsAstraZeneca

View Study Details

NCT03779854Recruiting

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant....

Iowa City, IAPHASE268 participantsFred Hutchinson Cancer Center

View Study Details

NCT04919382Recruiting

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metasta...

Iowa City, IAPHASE256 participantsDwight Owen

View Study Details

NCT06533098Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT)....

Iowa City, IAPHASE350 participantsJanssen Research & Development, LLC

View Study Details

NCT07177079Recruiting

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

This is a randomized, open-label, Phase I clinical study with expansion. It will assess the safety and efficacy of high-dose ascorbate administered concomitantly with azacitidine and venetoclax in new...

Iowa City, IAPHASE130 participantsKittika Poonsombudlert

View Study Details

NCT06107374Recruiting

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

This pilot study uses \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors. The study's main objectives are to...

Iowa City, IAPHASE220 participantsCellSight Technologies, Inc.

View Study Details

NCT06084806Recruiting

Test-retest Evaluation of [18F]F-AraG PET

This pilot study aims to evaluate the test-retest variability of \[18F\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \[18F\...

Iowa City, IAPHASE210 participantsCellSight Technologies, Inc.

View Study Details

About Leukemia Clinical Trials in Iowa City

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 15 leukemia clinical trials recruiting participants in Iowa City, IA. These studies are seeking a combined 2,488 participants. Research is being sponsored by Seagen, a wholly owned subsidiary of Pfizer, Syndax Pharmaceuticals, Priothera SAS and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Iowa City — FAQ

Are there leukemia clinical trials in Iowa City?

Yes, there are 15 leukemia clinical trials currently recruiting in Iowa City, IA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Iowa City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Iowa City research site will contact you about next steps.

Are clinical trials in Iowa City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Iowa City studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 15 active trials in Iowa City are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 18, 2026 from ClinicalTrials.gov